Giammarco Fava

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/840782/publications.pdf

Version: 2024-02-01

39 papers	2,025 citations	218677 26 h-index	289244 40 g-index
42 all docs	42 docs citations	42 times ranked	2074 citing authors

#	Article	IF	Citations
1	Locally acquired hepatitis E virus in Marche Italy: Clinical/laboratory features and outcome. Digestive and Liver Disease, 2020, 52, 434-439.	0.9	4
2	Clinical and patient reported outcomes of the multidisciplinary management in patients with inflammatory bowel disease-associated spondyloarthritis. European Journal of Internal Medicine, 2019, 64, 76-84.	2.2	9
3	Functional roles of gut bacteria imbalance in cholangiopathies. Liver Research, 2019, 3, 40-45.	1.4	6
4	Sclerostin and Antisclerostin Antibody Serum Levels Predict the Presence of Axial Spondyloarthritis in Patients with Inflammatory Bowel Disease. Journal of Rheumatology, 2018, 45, 630-637.	2.0	23
5	Gut Microbiota and Alcoholic Liver Disease. Reviews on Recent Clinical Trials, 2016, 11, 213-219.	0.8	26
6	Postoperative Insulin-Like Growth Factor 1 Levels Reflect the Graftâ€™s Function and Predict Survival after Liver Transplantation. PLoS ONE, 2015, 10, e0133153.	2.5	8
7	ALPPS Procedure for Extended Liver Resections: A Single Centre Experience and a Systematic Review. PLoS ONE, 2015, 10, e0144019.	2.5	42
8	[Tenofovir and entecavir for chronic hepatitis B infection treatment: a single-center experience]. Clinical Management Issues, 2015, 9, 95-100.	0.3	0
9	VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICEâ€1 study. International Journal of Cancer, 2014, 135, 1247-1256.	5.1	109
10	An oestrogen receptor Î²-selective agonist exerts anti-neoplastic effects in experimental intrahepatic cholangiocarcinoma. Digestive and Liver Disease, 2012, 44, 134-142.	0.9	34
11	Cholangiocarcinoma in Italy: A national survey on clinical characteristics, diagnostic modalities and treatment. Results from the â€œCholangiocarcinomaâ€•committee of the Italian Association for the Study of Liver disease. Digestive and Liver Disease, 2011, 43, 60-65.	0.9	59
12	Neuropeptide Y inhibits cholangiocarcinoma cell growth and invasion. American Journal of Physiology - Cell Physiology, 2011, 300, C1078-C1089.	4.6	27
13	Molecular mechanisms of cholangiocarcinoma. World Journal of Gastrointestinal Pathophysiology, 2010, 1, 12.	1.0	25
14	After Damage of Large Bile Ducts by Gamma-Aminobutyric Acid, Small Ducts Replenish the Biliary Tree by Amplification of Calcium-Dependent Signaling and de Novo Acquisition of Large Cholangiocyte Phenotypes. American Journal of Pathology, 2010, 176, 1790-1800.	3.8	68
15	Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis. Gut, 2009, 58, 990-997.	12.1	58
16	Control of Cholangiocyte Adaptive Responses by Visceral Hormones and Neuropeptides. Clinical Reviews in Allergy and Immunology, 2009, 36, 13-22.	6.5	28
17	Endothelin inhibits cholangiocarcinoma growth by a decrease in the vascular endothelial growth factor expression. Liver International, 2009, 29, 1031-1042.	3.9	33
18	Human cholangiocarcinoma development is associated with dysregulation of opioidergic modulation of cholangiocyte growth. Digestive and Liver Disease, 2009, 41, 523-533.	0.9	12

#	Article	IF	Citations
19	Leptin Enhances Cholangiocarcinoma Cell Growth. Cancer Research, 2008, 68, 6752-6761.	0.9	77
20	Thyroid hormone inhibits biliary growth in bile duct-ligated rats by PLC/IP3/Ca2+-dependent downregulation of SRC/ERK1/2. American Journal of Physiology - Cell Physiology, 2007, 292, C1467-C1475.	4.6	19
21	Cholangiocyte Injury and Ductopenic Syndromes. Seminars in Liver Disease, 2007, 27, 401-412.	3.6	43
22	Molecular pathology of biliary tract cancers. Cancer Letters, 2007, 250, 155-167.	7.2	45
23	Glucagon-Like Peptide-1 and Its Receptor Agonist Exendin-4 Modulate Cholangiocyte Adaptive Response to Cholestasis. Gastroenterology, 2007, 133, 244-255.	1.3	73
24	Prolactin stimulates the proliferation of normal female cholangiocytes by differential regulation of Ca2+-dependent PKC isoforms. BMC Physiology, 2007, 7, 6.	3.6	35
25	H3 histamine receptor agonist inhibits biliary growth of BDL rats by downregulation of the cAMP-dependent PKA/ERK1/2/ELK-1 pathway. Laboratory Investigation, 2007, 87, 473-487.	3.7	77
26	Cytoprotective effects of taurocholic acid feeding on the biliary tree after adrenergic denervation of the liver. Liver International, 2007, 27, 558-568.	3.9	23
27	Novel interaction of bile acid and neural signaling in the regulation of cholangiocyte function. Hepatology Research, 2007, 37, S420-9.	3.4	6
28	Ca2+-Dependent Cytoprotective Effects of Ursodeoxycholic and Tauroursodeoxycholic Acid on the Biliary Epithelium in a Rat Model of Cholestasis and Loss of Bile Ducts. American Journal of Pathology, 2006, 168, 398-409.	3.8	68
29	Vascular Endothelial Growth Factor Stimulates Rat Cholangiocyte Proliferation Via an Autocrine Mechanism. Gastroenterology, 2006, 130, 1270-1282.	1.3	188
30	Endogenous Opioids Modulate the Growth of the Biliary Tree in the Course of Cholestasis. Gastroenterology, 2006, 130, 1831-1847.	1.3	41
31	Adrenergic receptor agonists prevent bile duct injury induced by adrenergic denervation by increased cAMP levels and activation of Akt. American Journal of Physiology - Renal Physiology, 2006, 290, G813-G826.	3.4	55
32	Administration of r-VEGF-A prevents hepatic artery ligation-induced bile duct damage in bile duct ligated rats. American Journal of Physiology - Renal Physiology, 2006, 291, G307-G317.	3.4	67
33	Nervous and Neuroendocrine regulation of the pathophysiology of cholestasis and of biliary carcinogenesis. World Journal of Gastroenterology, 2006, 12, 3471.	3.3	25
34	Heterogeneity of the intrahepatic biliary epithelium. World Journal of Gastroenterology, 2006, 12, 3523.	3.3	75
35	The Immunophysiology of Biliary Epithelium. Seminars in Liver Disease, 2005, 25, 251-264.	3.6	46
36	Î³-Aminobutyric Acid Inhibits Cholangiocarcinoma Growth by Cyclic AMPâ€“Dependent Regulation of the Protein Kinase A/Extracellular Signal-Regulated Kinase 1/2 Pathway. Cancer Research, 2005, 65, 11437-11446.	0.9	85

#	Article	IF	Citations
37	Autocrine/paracrine regulation of the growth of the biliary tree by the neuroendocrine hormone serotonin. Gastroenterology, 2005, 128, 121-137.	1.3	226
38	cAMP stimulates the secretory and proliferative capacity of the rat intrahepatic biliary epithelium through changes in the PKA/Src/MEK/ERK1/2 pathway. Journal of Hepatology, 2004, 41, 528-537.	3.7	110
39	Î±-1 adrenergic receptor agonists modulate ductal secretion of BDL rats via Ca2+- and PKC-dependent stimulation of cAMP. Hepatology, 2004, 40, 1116-1127.	7.3	61